DIAGNOS Announces the Signing of a Letter of Intent With a Major Global Pharma in India

DIAGNOS inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), leader in
healthcare technical services including, screening, software and algorithm
development, data analysis, and image processing, announces today the signing of
a Letter of Intent ("LOI") with a major global pharmaceutical partner, for the
joint deployment and usage of CARA in India.


As part of its mission to discover, develop and successfully market innovative
products to prevent and cure diseases, to ease suffering and to enhance the
quality of life, our partner organization supports various health organizations
and health initiatives, including population screening, in India. The partner
organisation views our CARA screening platform as an excellent tool within the
context of their activities in India. Their lead ophthalmology product is
indicated for a variety of ophthalmic complications including those associated
with diabetes, and with our assistance they hope to slow or reverse vision
impairment in a larger patient population. 


"Recognizing the elevated rate of diabetes and its complications in the area, we
have been involved in projects in the region for some time now, and are in a
position to materially and constructively help local authorities with critical
screening projects. Our Partner's leadership and support can make these
initiatives feasible and can undoubtedly greatly benefit the local population.
We are very excited with this important relationship. Under the terms of the
present LOI, DIAGNOS would deploy mobile screening units comprising our CARA
platform, screening van, licensed optometric screener, and driver. The teams
would initially be located in Mumbai and New Delhi with coverage of 500km radius
around the respective cities. The screening units would travel to cities, towns,
and villages in the designated coverage areas to conduct mobile screening camps
in association with participating primary and tertiary healthcare institutions."
Said Peter Nowacki, Diagnos' Vice-President - Healthcare.


"We are excited to partner with our client, an important multinational
organization, to offer screening services based on our CARA platform and
screening processes we have developed and adapted internationally. The nature of
the relationship offers the potential of scaling-up across the vast population
and size of India. With an estimated diabetic population in India of over 73
million people the potential for DIAGNOS is very large and we are actively
working on establishing required local infrastructure to handle this project, as
well as pursuing additional volume-generating relationships. Under the terms of
the present LOI, DIAGNOS would receive payments locally covering local costs
leading to local profit margins, along with a royalty stream to DIAGNOS Inc. for
the usage of the CARA Platform. We believe that the lower cost dynamics in India
coupled with a large volume potential across the country to be strong drivers of
value for DIAGNOS shareholders." Said Andre Larente, Diagnos' President.


About CARA

CARA is a tele-ophthalmology platform that integrates with ophthalmic imaging
equipment (hardware and software) and processes at the point of care (POC) and
comprises: image upload, image enhancement automated pre-screening, grading by a
specialist, and referral to a specialist. CARA's image enhancement algorithms
make standard retinal images sharper, clearer, and easier to read. CARA is
accessible securely over the internet, and is compatible with all recognized
image formats and brands of fundus cameras, and is EMR compatible. CARA is a
cost-effective tool for screening large numbers of patients, in real-time and
has been approved by regulatory authorities including Health Canada, US Food and
Drug Administration, and the European Union.


About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation (TSX
VENTURE:ADK), with a mission to commercialize technologies combining contextual
imaging and traditional data mining thereby improving decision making processes.
DIAGNOS offers products, services, and solutions to clients in a variety of
fields including healthcare and natural resources.


Neither the TSX Venture Exchange nor its Regulation Service Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


For further information on DIAGNOS, please visit our website at www.diagnos.com
or the SEDAR website at www.sedar.com 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Andre Larente, President
DIAGNOS Inc.
450-678-8882, 224


Louis Morin
Bid Capital Markets
514-845-1101
Diagnos (TSXV:ADK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024